Hospital.Help

Venice – A new analysis of data from the SELECT cardiovascular outcomes study suggests that the cardiovascular benefits of semaglutide do not appear to depend on how many pounds patients lose. This is what researchers reported at the European Congress on Obesity in Venice. Long-term data from SELECT, also presented at the congress, also show that the weight loss achieved with semaglutide lasts over 4 years – and…